Bioventus Inc. 10-Q Summary: Quarter Ended September 28, 2024
Business Context and Reporting Period
Bioventus Inc. is a global medical device company focused on minimally invasive treatments, operating through U.S. and International segments. The company reported results for the three and nine months ended September 28, 2024. Bioventus is classified as an accelerated filer, smaller reporting company, and emerging growth company. The company operates under an umbrella partnership C-Corporation (UP-C) structure, consolidating Bioventus LLC (BV LLC) while reporting a noncontrolling interest.
Key Financial Metrics
| Metric | Three Months Ended Sept 28, 2024 | Nine Months Ended Sept 28, 2024 |
|---|---|---|
| Net Sales | $138.96 million | $419.64 million |
| Gross Profit | $93.55 million (67.3% margin) | $285.57 million (68.1% margin) |
| Operating Income (Loss) | $4.07 million | $(19.97) million |
| Net Loss (Continuing Ops) | $(5.42) million | $(43.52) million |
| Net Loss Attributable to Bioventus | $(4.82) million | $(33.39) million |
| Adjusted EBITDA | $23.56 million | $80.63 million |
| Cash and Equivalents | $43.07 million | $43.07 million (as of Sept 28) |
| Total Debt (Gross) | $386.13 million | $386.13 million (as of Sept 28) |
| Operating Cash Flow | N/A | $19.47 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.0% year-over-year for the quarter and 11.3% for the nine-month period, driven primarily by volume growth in Pain Treatments (Durolane) and Surgical Solutions.
- Impairment Charges: The company recorded a non-cash impairment charge of $33.9 million for the nine months ended September 28, 2024, related to the Advanced Rehabilitation Business (ARB) classified as held for sale. This compares to a $78.6 million impairment in the prior year related to the divested Wound Business.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 16.1% for the quarter and 12.8% for the nine-month period. The nine-month increase was largely due to $11.4 million in legal costs related to shareholder litigation settlements and higher compensation costs.
- Profitability: While GAAP net loss narrowed significantly compared to the prior year (which included discontinued operations losses), the company reported a GAAP operating loss for the nine-month period due to impairment charges and litigation costs. Adjusted EBITDA improved to $80.6 million for the nine months, up from $66.8 million in the prior year.
Guidance, Outlook, and Risks
- Divestiture of Advanced Rehabilitation Business: On September 30, 2024, Bioventus entered an agreement to sell its non-core Advanced Rehabilitation Business. The deal includes $25.0 million at closing and up to $20.0 million in earn-outs. Proceeds are required to be used to reduce long-term debt. The transaction is expected to close late 2024 or early 2025.
- Debt Covenants: The company amended its Credit Agreement in January 2024. It is currently in compliance but must maintain liquidity of at least $10.0 million monthly until the fiscal quarter ending October 29, 2025.
- Legal Proceedings: A shareholder class action lawsuit (Ciarciello v. Bioventus) reached a preliminary settlement of $15.25 million, subject to court approval in December 2024. The company incurred $13.7 million in related costs during the nine months ended September 28, 2024, with an expected reimbursement of $6.5 million.
- Regulatory Risks: Risks include potential FDA reclassification of hyaluronic acid products from devices to drugs and the proposed down-classification of non-invasive bone growth stimulators, which could increase competition.
- Outlook: Management believes current cash, operating cash flows, and revolver availability are sufficient to meet needs for at least 12 months. Future liquidity may be supplemented by equity financing or further divestitures.
Investor Verification Checklist
- Divestiture Closing: Verify the closing date and final proceeds of the Advanced Rehabilitation Business sale to confirm debt reduction plans.
- Shareholder Litigation: Monitor the final court approval of the $15.25 million settlement and the actual receipt of the $6.5 million insurance reimbursement.
- Debt Covenant Compliance: Track monthly liquidity levels to ensure compliance with the $10.0 million minimum liquidity covenant required through late 2025.
- Product Pipeline: Assess the commercial launch timeline for the FDA-cleared Allograft Delivery Device (Q4 2024) and its impact on Surgical Solutions revenue.
- Noncontrolling Interest: Review the potential dilution impact if the Continuing LLC Owner (Smith & Nephew) exercises its right to exchange LLC interests for Class A common stock.